

Curriculum Vitae:

Thurman Allen Merritt, B.A., M.D., MPA:HA 2009

PERSONAL DATA:

Date of Birth	July 9, 1946
Birth Place	Wichita, Kansas
Citizenship	United States of America
Married	Maryanne G. Merritt 9/17/77
Children	Travis Allen Merritt 3/3/86 Willamette University BA, LLU Loma Linda University MPH Bryce Allen Merritt 2/10/87 Stanford University BS 09
Residence	25742 Mariposa Street Loma Linda, California 92354 (909) 796 8502
Professional Address	Loma Linda Univ. Medical Center 11175 Campus St. Coleman Pavilion 11121 Division of Neonatology Loma Linda, California 92354 (909) 558 7448

MEDICAL LICENCES:

Oregon 19863
Washington 35754
California G 28294
New York (Inactive)
Alaska A1907 (Inactive)

EDUCATION:	1960-64	Wichita High High School East Wichita, Kansas 67201
	1964-68	University of Kansas Lawrence, Kansas 66045 B.A. Cum Laude (Zoology)
	1968-72	Kansas University School of Medicine Kansas City, Kansas 66160 M.D. Cum Laude

1996-98	Portland State University Portland, Oregon 97120 MPA:HA Healthcare Admin. Executive Management Institute
---------	---

HOSPITAL TRAINING:

1972-1973	Pediatric Internship Kansas University Medical Center Kansas City, Kansas Director: H.C. Miller, M.D.
-----------	--

1973-1975	U.S. Public Health Service NICHD, NIH Bethesda, Maryland Pediatric Medical Officer Laboratory: Dr. Phillip Farrell
-----------	--

1975-1976	Pediatric Resident Univ. California, San Diego San Diego, California Chair: Dr. William Nyhan
-----------	--

1976-1978	Fellow, Neonatal/Perinatal Med. Univ. California, San Diego San Diego, California Director: Dr. Louis Gluck
-----------	--

ACADEMIC APPOINTMENTS:

1978-1981	Assistant Professor, Pediatrics and Obstetrics University of Rochester Rochester, New York
-----------	---

1981-1990	Assistant, Associate and Full Professor University of California, San Diego, School of Medicine LaJolla, California
-----------	---

1990-1996	Professor and Division Chief Neonatology, University of California, Davis
-----------	---

1996-Present	Professor Emeritus, Professor
--------------	-------------------------------

University of California, Davis
School of Medicine, Davis, Ca.

1998-2006

Adjunct Professor, Oregon State
State Univ., Central Oregon
Community College
Allied Health Professions
Bend, Oregon

2007–Present

Professor of Pediatrics
Loma Linda University
School of Medicine,
Loma Linda, California

HOSPITAL APPOINTMENTS:

1978-81

Neonatology Faculty
Strong Memorial Hospital
Rochester, New York

1981-1990

Faculty Neonatologist
Univ. California, San Diego
Medical Center
San Diego, California

1990-1996

Division Chief, Neonatology
Univ. California, Davis Med Ctr
Sacramento, California

1996-2006

Director, Neonatology
St. Charles Medical Center
Bend, Oregon

1996-2006

Pediatric Neonatal/Pediatric
Practice, Central Oregon
Pediatrics Asso.
Bend, Oregon

2007-present

Neonatologist/Pediatrican
Loma Linda University
Children's Hospital
Loma Linda, California

FEDERAL/MILITARY SERVICE:

1973-1975

US Public Health Service
National institute of Child Health

and Human Development

1975-1984
1984-1991

Reserve Officer, USPHS
U.S. Army, Reserve, Major MC

BOARD CERTIFICATIONS:

1975	National Board of Medical Examiners I,II,III
1978 Lifetime	American Board of Pediatrics
1979 Lifetime	American Board of Pediatrics, Sub-Board Neonatal/Perinatal Medicine
1996	Recertification in General Pediatrics and Neonatal/Perinatal Medicine
1999=2008	National Board of Medical Quality Assurance and Utilization Review

PEDIATRIC CERTIFICATIONS:

1989-Present	Basic Life Support
1991-Present	Neonatal Resuscitation Program-Regional Instructor
1989-Present	Pediatric Advanced Life Support

APPOINTMENTS:

2001-2006	Appointed as State Commissioner, Oregon Commission for Children and Families By Governor John Kitzhaber, MD. Confirmed by Oregon Senate Reappointed by Governor Ted Kulongoski
2008-2009	Appointed to Premie Taskforce, DHS, Sacramento, Ca

HONORS:

1967-68	National Science Foundation, Undergraduate Research Award
	L.A. Calkins Award for Research
1972	Daniel Darrow, M.D. Award Outstanding Graduate in Pediatrics, University of Kansas School of Medicine
1980	Faculty Teacher of the Year, University of Rochester, Department of Pediatrics
1987	U.S. Army Achievement Medal
1988	Juselius Foundation, Finnish Academy of Sciences, Visiting Scholar in Research
1989	Greater New York, Distinguished Professor March of Dimes, NYU School of Medicine
1994	BenGurion University of Negeev, Israel, Israeli Perinatal Society, Visiting Professor

1996	Bilderback Lecture in Perinatal Medicine Oregon Health Sciences University
2000-2009	Best Doctor's in America (Western Region)
2003	Oregon Medical Association, Citizen- Physician of the Year
2008	Elected to Board of Director, California Asso. Neonatologists

CONSULTATIONS TO FEDERAL/STATE AGENCIES:

1986	Pulmonary Advisory Committee, FDA
1989	Pulmonary/Allergy Advisory Committee FDA, Surfactant
1984-86	NIH Study Section, NHLBI, SCOR, GCRC, Pulmonary SCOR
1987	NICHD-Special Study Section, Apnea
1999	NHLBI, Study Section, Clinical Trials
2002	NHLBI, BPD Study Section
1996	Medical Research Council, Canada
1997-2004	Nevada Health Department NICU Surveyor
1997-2005	Oregon Board of Medical Examiners Reviewer of Selected Cases before the Board
1995-1996	California Medical Board-Medical Reviewer
1997-2006	Oregon Health Division, Newborn Hearing Screening and Environmental Health-Lead Poisoning, Tobacco Exposure

PROFESSIONAL SOCIETIES:

1978	American Academy of Pediatrics
1979	Sections of Perinatal Medicine, Transport
1982	Elected to Society for Pediatric Research
1984	American Thoracic Society-Pediatric Section
1994,2008	California Assoc of Neonatologists (Board)
1996	Oregon Medical Association-Trustee/Delegate
1998	Academy of Breastfeeding Medicine
2007	Perinatal Action Committee, Los Angeles County (Board of Directors)

GRANTS as PI/CoPI:

1976-1978	NIH F32 Fellowship in Perinatal Medicine
1979-1984	HD RO1 Newborn Tracheal Aspirates
1985-1991	HL RO1 Human Surfactant Clinical Trials
1986-1990	HL SCOR UC San Diego
1991-1994	HL SCOR UC Davis
1986-1991	FDA Orphan Drug Program-Human Surfactant and Neonatal Follow up
1991-1995	Primate Research Center Program Project
2001,2003	HRSA-CATCH grant-Medical Home Premie Follow-up

2007	Oxidation of Surfactant formation of Isoprostanes-Discovery Laboratories
2008	Julius Richmond Foundation-Effects of Maternal Smoking on Lactation
2008	March of Dimes-Smoking Cessation among Pregnant Mothers
2009	NIH-Neonatal Hypotension Role of Adrenal Immaturity Funded Challenge Grant

REQUESTED REVIEWER:

Journal of Clinical Investigation Pediatric Research Am. J. Obst and Gynecol Science
J. Perinatology Seminars in Perinatology Biology of the Neonate Pediatrics Lung
J. Pediatrics New England J. Medicine Biochemistry Arch Diseases of Childhood
Perinatal Clinics of North America Laboratory Medicine Am. J. Physiology
Anesthesiology
J. Managed Care J. Evidence Based Medicine Obstet Gynecol Acta Paediatrica , Archives
of the Diseases of Children Fetal and Neonatal Edition.

REQUESTED EDITORIALS:

New England J. Medicine, 1991, 1996: Am. J. Diseases of Children 1992; Pediatrics
1995, 1997, Pediatric Pulmonology 1993
Journal of Clinical Investigation 1996, Seminars in Perinatology 2003.

INTERNATIONAL/NATIONAL REVIEW COMMITTEES:

1986-2002	National Foundation March of Dimes
1996-2000	Johnson and Johnson Pharmaceutical Research Foundation
1996-2006	Discovery Laboratories, Clinical Research Review Committee
1995-1997	rh-SOD Chair, Data Safety Monitoring Committee, International Clinical Trial, Biotechnology General, Israel Canadian PROM Study, Women's College Hospital, McMaster Univ
1997-99	Finnish Academy of Sciences, Helsinki, Finland
2000-2005	Northwest Foundation, Foundation for Medical Excellence
2007-2008	Will Rogers institute, Lake Tuluca, California
2008	Michigan Tobacco Tax Research Grant Fund-Hutzel Hospital

ORGANIZATIONAL GOVERNING COMMITTEES:

Member Institutional Review Board, UC San Diego, Chair, Institutional Review Board,
Cascade Healthcare, Executive Committee, UC Davis, Chair Bioethics

Committee, Cascade Healthcare, Legislative Committee, Oregon Medical Association,
Child Advocacy/Safety Committee, Diocese of Baker, Bishop Robert Vasa, Board of
Directors, St. Charles Medical Foundation, State Commissioner,

Oregon Commission for Children and Families, Chief of Professional Services, 63rd ARCOM U.S. Army Reserve, Knights of Columbus Oregon Council, Executive Committee, Central Oregon Medical Society, Trustee Oregon Medical Association, Elected to Board of Directors, California Association of Neonatologists, Elected to Board of Perinatal Action Committee/Los Angeles County and Inland Empire/Loma Linda University Medical Center Ethics Committee.

PEER REVIEWED PUBLICATIONS-T. ALLEN MERRITT, M.D, MPA:HA

1. 1975 Merritt, T.A. and Dudding, B. The sudden infant death syndrome: A challenge for Kansas physicians. *J. Kansas Medical Society*, 76: 29-33.
2. 1975 Merritt, T.A., Bauer, W.I., Hasselmeyer, E.G. Sudden infant death syndrome: Role of emergency medical care. *Clinical Pediatrics* 14: 1095-1097.
3. 1976 Merritt, T.A., and Farrell, P.M. Diminished pulmonary lecithin synthesis in acidosis: Experimental findings as related to respiratory distress syndrome. *Pediatrics* 57: 32-40.
4. 1976 Naeye, R.L. Messmer, L., Specht, T. and Merritt, T.A. Sudden Infant death syndrome: temperament before death. *J. Pediatrics* 88: 511-515.
5. 1977 Gellis, S., Feingold, M., Merritt, T.A., Slaughter, R. Cutis marmorata telangiectasia congenital. *Am J. Dis. Child.* 131: 1027-1028.
6. 1978 Merritt, T.A., DiSessa, T.G., Feldman, B.G., Kirkpatrick, S.E., Gluck, L. and Friedman, W.F. Closure of the patent ductus arteriosus arterious with ligation and indomethacin : a consecutive experience. *J. Pediatrics.* 93: 639-646.
7. 1978 Merritt, T.A., Gluck, L., Higgins, C., Friedman, W.F. and Nyhan, W.L. Management of premature infants with patent ductus arteriosus. *Western J. Medicine* 128(3) 212-213.
8. 1978 Friedman, W.F., Fitzpatrick, K.M., Merritt, T.A., and Feldman, B.H. The patent ductus arteriosus. *Clinics in Perinatology* 5: 411-435.
9. 1978 Edwards, D.K., Higgins, C.B., Merritt, T.A., DiSessa, T.G. and Friedman, W.F. Radiographic and echocardiographic evaluation of newborns treated with indomethacin for patent ductus arteriosus. *Am. J. Roentgenology* 131: 1009-1013.
10. 1978 Ballard, R., Vincour, B., Reynolds, J., Merritt, T.A., Sweetman, L. and Nyhan, W.L. Transient hyperammonemia of the preterm infant. *New England J. Med.* 299: 920-923.
11. 1979 Merritt, T.A., White, C.L., Jacob, J., Kurlinski, J., Martin, J., DiSessa,

- T., Edwards, D., Friedman, W.F., and Gluck, L. Patent ductus arteriosus treated with ligation or indomethacin: A follow-up study. *J. Pediatrics* 95: 588-591.
12. 1979 Obladen, M., Merritt, T.A., and Gluck, L. Acceleration of pulmonary surfactant maturation in stressed pregnancies: a study of neonatal lung effluent. *Am. J. Obstet and Gynecol.* 135: 1079-1086.
 13. 1980 Jacob, J., Gluck, L., DiSessa, T., Edwards, D., Kulovich, M., Kurlinski, J., Merritt, T.A., Friedman, W.F. Contribution of the PDA in the neonate with severe RDS. *J. Pediatrics* 96: 79-87.
 14. 1980 Friedman, W.F., Kurlinski, J., Jacob, J., DiSessa, T.G., Gluck, L. Merritt, T.A., and Feldman, B.H. The inhibition of prostaglandin and prostacyclin synthesis in the clinical management of the patent ductus arteriosus. *Seminars in Perinatology* 4: 125-133.
 15. 1980 Zmora, E. and Merritt, T.A. Use of side-hole endotracheal tube adaptor for tracheal aspiration: a controlled study. *Am J. Diseases of Children.* 134: 250: 250-254.
 16. 1980 Merritt, T.A., Lawrence, R.A., and Naeye, R.L. The infants of adolescent mothers. *Pediatric Annals* 9: 100-110.
 17. 1980 Clarke, T.A., Zmora, E., Chen, J.H., Reddy, G. and Merritt, T.A. Transcutaneous oxygen monitoring during neonatal transport. *Pediatrics* 65: 884-886.
 18. 1980 Merritt, T.A., Lawrence, R.A., and Naeye, R.L. Adolescent pregnancy outcome. *Pediatric Annals* 9: 100-106.
 19. 1980 Sweetman, L., Nyhan, W.L., Tauner, D.A., Merritt, T.A., and Singh, M. Glutaric Aciduria Type II. *J. Pediatrics* 96: 1020-1026.
 20. 1980 Porreco, R.P., Merritt, T.A., and Gluck, L. Effects of prolactin on phospholipids biosynthesis by alveolar cell carcinoma (A549) in monolayer tissue culture. *Am J. Obstet. And Gynecol.* 136: 1071-1074.
 21. 1981 Merritt, T.A., Curbelo, V., Gluck, L., and Clements, R.S. Alterations of fetal lung phosphatidylinositol metabolism associated with maternal glucose intolerance. *Biology of the Neonate* 39: 217-224.
 22. 1981 Merritt, T.A., Liyamasawad, S., Boettrich, C., and Brooks, J.G. Skin surface CO₂ measurement in sick preterm and term infants. *J. Pediatrics* 99: 782-786.
 23. 1981 Merritt, T.A., Stuard, I.D., Puccia, J., Edwards, D.K., Woods, B., Finkelstein, J. and Shapiro, D. Newborn tracheal aspirate cytology

classification during respiratory distress syndrome and bronchopulmonary dysplasia. *J. Pediatrics* 98: 949-956.

24. 1981 Lawrence, R.A. and Merritt, T.A. Infants of Adolescent Mothers: Perinatal, neonatal, and infancy outcomes. *Seminars in Perinatology* 5: 19-32.
25. 1981 Merritt, T.A., Harris, J.P., Roghman, K., Wood, B., Manning, J.K. and Shapiro, D. Early closure of the patent ductus arteriosus in very low birth weight infants: a controlled trial. *J. of Pediatrics* 99: 281-286.
26. 1981 Merritt, T.A., Puccia, J.M., and Stuard, I.D. Cytologic evaluation of pulmonary effluent in neonates with respiratory distress syndrome and bronchopulmonary dysplasia. *Acta Cytologica* 25: 631-639.
27. 1981 Merritt, T.A. Smoking mothers affect little lives. *Am. J. Disease of Children*. 135: 01-502.
28. 1982 Zmora, E. and Merritt, T.A. Control of peak inspiratory pressure during manual ventilation. A controlled study. *Am J. Dis. of Children*. 126: 46-48.
29. 1982 Merritt, T.A., Oxygen exposure in the newborn guinea pig lung lavage cell populations, chemotactic and elastase response: a possible relationship to neonatal bronchopulmonary dysplasia. *Pediatric Research* 16: 798-805.
30. 1982 Wood, B., Anderson, V.M., Mauk, J.E., and Merritt, T.A. Pulmonary lymphatic air: locating "pulmonary interstitial emphysema": of the premature infant. *Am. J. of Roentgenology*. 138: 809-814.
31. 1982 Merritt, T.A., White, C.L., Coen, R., Friedman, W.F., and Gluck, L. Preschool assessment of infants with a patent ductus arteriosus: comparison of ligation and indomethacin therapy. *Am. J. Diseases of Children* 136: 507-512.
32. 1982 Harris, J.P. , Merritt, T.A., Alexson, G.G., Longfield, L. and Manning, J.A. Parenteral indomethacin for closure of the patent ductus arteriosus: clinical experience with 67 preterm infants. *Am. J. Diseases of Children* 136: 1005-1008.
33. 1982 Bejar, R., Trauner, D., Merritt, T.A., James, H., and Gluck, L. Neonatal intra-ventricular hemorrhage: the dilemma of precise individual prognosis. *Perinatology/Neonatology* 6: 107-110.
34. 1982 Bejar, R.K., Merritt, T.A., Coen, R., Mannino, F., and Gluck, L. Pulsatility index, patent ductus arteriosus and brain damage. *Pediatrics* 69: 818-822.

35. 1982 Clarke, T.A., Edwards, D., Merritt, T.A., and Young, L.W. Radiological case of the month. *Am J. Diseases of Children* 136: 69.
36. 1983 Merritt, T.A., Cochrane, C.G., Holcomb, K., Bohl, B. Hallman, M. Strayer, D., Edwards, D.K., and Gluck, L. Elastase and alpha 1 proteinase inhibitor activity in tracheal aspirates during respiratory distress syndrome: role of inflammation in the pathogenesis of bronchopulmonary dysplasia. *Journal of Clinical Investigation*. 72: 656-666.
37. 1983 Merritt, T.A., Bejar, R., Corraza, M., Ikonen, R.A., Davis, R. and Rosenberg, M. Clinical trials of intravenous indomethacin for closure of the patent ductus arteriosus. *Pediatric Cardiology* 4: 71-76.
38. 1983 Merritt, T.A., Cochrane, C.G., Hallman, M., Holcomb, K., Strayer, D. Mannino, F., Edwards, D.K., and Gluck, L. Reduction of lung injury by human surfactant treatment in respiratory distress syndrome. *Chest* 83(5 Suppl): 27-22S.
39. 1983 Moodley, S., Liu, J.H., Cherkis, R.C., Miller, R.K., Merritt, T.A. and Whalen, L.E. Fetal pulmonary maturity: relationship between optical density (650 nm) to the lecithin/sphingomyelin ratio and phosphatidylglycerol in amniotic fluid. *International J. of Gynecology and Obstetrics* 21: 99-100.
40. 1983 Hallman, M., Merritt, T.A., Schneider, H., Epstein, B., Mannino, F., Edwards, D.K., and Gluck, L. Isolation of human surfactant from amniotic fluid and a pilot study of its efficacy in respiratory distress syndrome. *Pediatrics* 71: 473-482.
41. 1984 Merritt, T.A. and Rich, W.D. Clinical perspectives in neonatal apnea monitoring: a proposal for new innovations. AAMI technology assessment report. *Medical Technology (TAR 9-84)* 57-62.
42. 1984 Kashani, I., Schmunk, G.A., Merritt, T.A., Swensson, R.E., and Utley, J.R. Prostaglandin E₁ responsive ductus at 11 months of age. *Pediatric Cardiology* 15: 19-21.
43. 1984 Rich, W.D., Merritt, T.A., and Kopotic, R.J. Home apnea monitoring 1984: Evaluation of the performance of home cardiorespiratory monitoring equipment. *Perinatology/Neonatology* 8: 15-20.
44. 1984 Corazza, M.S., Davis, R.F., Merritt, T.A., Bejar, R., and Cvetnic, W. Prolonged bleeding time in preterm infants receiving indomethacin for patent ductus arteriosus. *J. Pediatrics* 105: 292-296.
45. 1984 James, H.E., Bejar, R., Gluck, L., Coen, R., Merritt, T.A. Mannino, F.,

- Bromberger, P., Saunders, B., Schneider, H. Ventriculoperitoneal shunts in high risk newborns weighing under 2000 grams: a clinical report. *Neurosurgery* 15: 198-204.
46. 1985 Edwards, D.K., Hilton, S., Merritt, T.A., Hallman, M., Mannino, F., and Boynton, B. Respiratory distress syndrome treated with human surfactant: radiographic findings. *Radiology* 157: 329-334.
 47. 1985 Boynton, B.R., Mannino, F.L., Randel, R.C., Merritt, T.A., Coen, R.W., Edwards, D.K., and Gluck, L. Minimizing bronchopulmonary dysplasia in VLBW infants. *J. Pediatrics* 104: 962-963.
 48. 1985 Hallman, M., Merritt, T.A., Cochrane, C. and Gluck, L. Human surfactant substitution in severe respiratory distress syndrome. *Progress in Respiration Research* 18: 193-201.
 49. 1985 Hallman, M., Merritt, T.A., Jarvenpaa, A.L., Boynton, B.R., Mannino, F., Gluck, L., Moore, T., and Edwards, D. Exogenous human surfactant for treatment of severe respiratory distress syndrome: a randomized prospective clinical trial. *J. Pediatrics* 106: 963-969.
 50. 1986 Strayer, D.S., Merritt, T.A., Lwebuga-Mukasa, J., and Hallman, M. Surfactant-antisurfactant immune complexes in infants with respiratory distress syndrome. *Am J. Pathology* 122: 353-362.
 51. 1986 Boynton, B.R., Boynton, C., Merritt, T.A., Vaucher, Y., James, H.E., and Bejar, R. Ventriculoperitoneal shunts in low birth weight infants with intracranial hemorrhage: Neurodevelopmental outcomes. *Neurosurgery*. 18: 141-145.
 52. 1986 Merritt, T.A., Hallman, M., Holcomb, K., Strayer, D., Bloom, B., Revak, S., and Cochrane, C.G. Human surfactant treatment of severe respiratory distress syndrome: pulmonary effluent indicators of lung inflammation. *J. Pediatrics* 108: 741-748.
 53. 1986 Ward, S.L.D., Keens, T.G., Chan, L.S., Chipps, B.E., Carson, S.H., Deming, D.D., Krishna, V., MacDonald, H.M., Martin, G.I., Meredith, K.S., Merritt, T.A., Nickerson, B.G., Stoddard, R.A., and van der Hal, A.L. Sudden infant death syndrome in infants evaluated by apnea programs in California. *Pediatrics* 77: 451-457.
 54. 1986 Haas, R.H., Rice, M.A., Trauner, D.A., Merritt, T.A. Therapeutic effects of a ketogenic diet in Rett syndrome. *Am J. Medical Genetics* 24: 225-246.
 55. 1986 Kashani, I.A., Richardson, B., Lammers, R.J., Merritt, T.A., Bloor, C.M. Effects of prostaglandins on the pulmonary vascular bed of newborn rats with chronic hypoxia. *Angiology* 37: 21-26.

56. 1986 Merritt, T.A., Hallman, M., Bloom, B.T., Berry, C., Benirschke, K., Sahn, D., Key, T., Edwards, D., Jarvenpaa, A.L., Pohjavouri, M. Prophylactic treatment of very premature infants with human surfactant. *New England Journal of Medicine* 315: 785-790.
57. 1986 Revak, S.D., Merritt, T.A., Hallman, M., and Cochrane, C.G. Reconstitution of surfactant activity using purified human apoprotein and phospholipids measured *in vitro* and *in vivo*. *American Review of Respiratory Diseases* 134: 1258-1265.
58. 1986 Bejar, R., Coen, R.W., Merritt, T.A., Vaucher, Y.E., Trice, J., Centeno, R. and Gilles, F. Focal necrosis of the white matter (periventricular leukomalacia) : sonographic, pathologic, and electroencephalographic features. *Am. J. of Neuroradiology*. 7: 1073-1079.
59. 1986 Hallman, M., Merritt, T.A., Pohjavouri, M., and Gluck, L. Effect of surfactant substitution: evaluation of surfactant phospholipids turnover, pool size, and the relationship to severity of respiratory failure. *Pediatric Research* 20: 1228-1235.
60. 1987 James, H.E., Boynton, B.R., Boynton, C.A., Merritt, T.A., Vaucher, Y.E., and Bejar, R.E., Severe intracranial hemorrhage and hydrocephalus in low-birthweight infants treated with CSF shunts. *Children's Nervous Systems* 3: 110-113.
61. 1987 Merritt, T.A., and Vaucher, Y.E. Infant follow-up programs: their impact on infants and families. *Journal of Developmental Behavioral Pediatrics* 8: 286-287.
62. 1987 James, H.E., Bejar, R., Merritt, T.A., Mannino, F., Vaucher, Y. A Coen, R. Insidious hydrocephalus in the preterm newborn following discharge from the nursery. *Pediatric Neuroscience* 12: 129-131.
63. 1987 Hallman, M., Teramo, K., Ylikorkala, O., and Merritt, T.A. Natural surfactant substitution in respiratory distress syndrome. *J. of Perinatal Medicine* 15: 463-468.
64. 1987 Boynton, B.R., and Merritt, T.A. Bronchopulmonary dysplasia pp 301-328. In L.R. Laraya-Cuasay and W.T. Hughes (Eds) *Interstitial Lung Disease in Children Vol II*. CRC Press Inc. Boca Raton, Fl.
65. 1988 Merritt, T.A., and Hallman, M. Surfactant replacement: a new era with many challenges in neonatal medicine. *Am. J. Disease of Children* 142: 1333-1336.
66. 1988 Merritt, T.A., and Hallman, M. Interactions in the immature lung

- protease-antiprotease mechanism of lung injury. Pp 117-130. In N. Finer (ed) Contemporary Issues in Fetal and Neonatal Medicine. Blackwell Scientific Publication, Boston, Mass.
67. 1988 Merritt, T.A., and Boynton, B.R. Clinical presentation of bronchopulmonary dysplasia. Pp. 179-184 In N. Finer (ed) Contemporary Issues in Fetal and Neonatal Medicine. Blackwell Scientific Publication, Boston, Mass.
 68. 1988 Merritt, T.A. and Hallman, M. Impact of surfactant therapy for respiratory distress in preventing or reducing bronchopulmonary dysplasia. pp. 343-350. In Finer, N. (ed) Contemporary Issues in Fetal and Neonatal Medicine. Blackwell Scientific Publication, Boston, Mass.
 69. 1988 Revak, S.D., Merritt, T.A., Degryse, E., Stefani, L., Courtney, M., Hallman, M., and Cochrane, C.G. Use of human surfactant low molecular weight (LMW) apoproteins in the reconstitution of surfactant biologic activity. Journal of Clinical Investigation 81: 826-833.
 70. 1988 Vaucher, Y.E., Merritt, T.A., Hallman, M., Jarvenpaa, A.L., Telsey, A.M., and Jones, B.L. Neurodevelopmental and respiratory outcome in early childhood after human surfactant treatment. Am J. Diseases of Children 142: 927-930.
 71. 1988 Telsey, A.M., Merritt, T.A., Dixon, S.D. Cocaine exposure in a term neonate-necrotizing enterocolitis as a complication. Clinical Pediatrics 27: 547-550.
 72. 1988 Merritt, T.A., Strayer, D.S., Hallman, M., Spragg, R.D. and Wozniak, P. Immunologic consequences of exogenous surfactant administration. Seminars of Perinatology 12: 221-230.
 73. 1988 Strayer, D.S., Merritt, T.A., Spragg, R. and Hallman, M. Immunogenicity of surfactant and its implications for replacement therapy, pp. 301-314. In B. Lachmann (Ed) Surfactant Replacement Therapy in Neonatal and Adult Respiratory Distress Syndrome. Springer-Verlag Publisher.
 74. 1988 Revak, S.D., Merritt, T.A., Hallman, M. and Cochrane, C.G. Reconstitution of human surfactant activity using low molecular weight apoproteins. pp 338-344. In B. Lachmann (Ed) Surfactant Replacement Therapy in Neonatal and Adult Respiratory Distress Syndrome. Springer-Verlag Publisher.
 75. 1988 Merritt, T.A., Hallman, M. and Edwards, D. Impact of surfactant therapy in preventing bronchopulmonary dysplasia. pp. 181-189. In B. Lachmann (Ed) Surfactant Replacement Therapy in Neonatal and

Adult Respiratory Distress Syndrome. Springer-Verlag Publisher.

76. 1988 Spragg, R.G., Richman, P., Gilliland, N., and Merritt, T.A. The future for surfactant therapy of the adult respiratory distress syndrome. pp. 203-212. In B. Lachmann (Ed) Surfactant Replacement Therapy in Neonatal and Adult Respiratory Distress Syndrome. Springer-Verlag Publisher.
77. 1988 Merritt, T.A., Hallman, M., Vaucher, Y.E., Berry, C. and Jarvenpaa, A.L. Clinical response to human surfactant. Pp 14-21 In B. Lachmann (Ed), Surfactant Replacement Therapy in Neonatal and Adult Respiratory Distress Syndrome. Springer-Verlag Publisher.
78. 1988 Hallman, M., Pohjavuori, M., Bry, K., and Merritt, T.A. Human surfactant from amniotic fluid in the treatment of respiratory distress syndrome, pp 136-143. In B. Lachmann (Ed) Surfactant Replacement Therapy in Neonatal and Adult Respiratory Distress Syndrome. Springer-Verlag Publisher.
79. 1988 Heldt, G., Merritt, T.A., Pesonen, E. Hallman, M, and Sahn, D. Surfactant therapy does not adversely influence closure of the patent ductus arteriosus, pp. 91-97. In A.H. Jobe and H.W. Taesch (Eds) Surfactant Treatment of the Lung. 96th Ross Conference, December 12, 1988.
80. 1988 Hallman, M., Pitkanen, O., Merritt, T.A., and Arjomaa, P. Surfactant metabolism in the respiratory distress syndrome. pp 69-71. In A.H. Jobe and H.W. Taeusch (Eds) Surfactant Treatment of the Lung. 96th Ross Conference, December 12, 1988.
81. 1989 Heldt, G.P., Pesonen, E., Merritt, T.A., Elias, W., and Sahn, D. Closure of the ductus arteriosus and mechanics of breathing in preterm infants after surfactant replacement therapy. Pediatric Research 25: 305-310.
82. 1989 Strayer, D.S., Merritt, T.A., Makunike, C., and Hallman, M. Antigenicity of low molecular weight surfactant species. American Journal of Pathology 134: 723-732.
83. 1989 Merritt, T.A., Strayer, D.S., Hallman, M., and Spragg, R. Immunologic considerations regarding exogenous surfactants, pp 145-163. In D.L. Shapiro and R.H. Notter (Eds) Surfactant Replacement Alan R. Liss, Inc., New York.
84. 1984 Hallman, M., Merritt, T.A. Human amniotic fluid surfactant: Clinical trial experiences, pp 235-255. In D.L. Shapiro and R.H. Notter (Eds) Surfactant Replacement Alan R. Liss, Inc. New York.
85. 1985 Sherman, M.P., Campbell, L.A., Merritt, T.A., Long, W., Gunkel, H.,

- Curstedt, T., Robertson, B. The infected preterm rabbit lung. *Progress in Respiratory Research* 25: 1-4.
86. 1989 Hallman, M., Pohjavuori, M., Jarvenpaa, A.L., Bry, K., Merritt, T.A. and Pesonen, E. Human surfactant in the treatment of respiratory distress syndrome. A spectrum of clinical responses. *European Respiratory Journal* 3: 77s-80s.
 87. 1989 Strayer, D.S., Merritt, T.A., Hallman, M. Surfactant replacement: immunological considerations. *European Respiratory Journal*. 3:91s-96s.
 88. 1989 Richman, P.S., Spragg, R.G., Robertson, B. and Merritt, T.A. The adult respiratory distress syndrome: First trials with surfactant replacement. *European Respiratory Journal* 3: 109s-111s.
 89. 1990 Golembeski, D. and Merritt, T.A. New strategies for prevention of neonatal respiratory distress syndrome: Acceleration of fetal lung maturation and exogenous surfactant replacement. *Seminars in Respiratory Medicine* 11: 117-126.
 90. 1990 Pesonen, E., Merritt, T.A., Heldt, G., Sahn, D.J., Elias, W., Tikkanen, I., Fyhrquist, F. and Andersson, S. Correlation of patent ductus arteriosus shunting with plasma atrial natriuretic factor concentrations in preterm infants with respiratory distress syndrome. *Pediatric Research* 27: 137-139.
 91. 1990 Lang, M., Hall, R.T., Reddy, N.S., Kurth, C.G., and Merritt, T.A. A controlled trial of human surfactant replacement therapy for severe respiratory distress syndrome in very low birth weight infants. *J. Pediatrics* 116: 295-300.
 92. 1990 Gilliard, N., Richman, P.M., and Merritt, T.A. Effect of volume and dose on the pulmonary distribution of exogenous surfactant administered to normal rabbits or to rabbits with oleic acid lung injury. *American Review of Respiratory Disease* 141: 743-747.
 93. 1990 Merritt, T.A., Hallman, M., Yaucher, Y., McFeeley, E., and Tubman, T.R.J. Impact of surfactant treatment on cost of neonatal intensive care: A cost-benefit analysis. *Journal of Perinatology* 10: 416-419.
 94. 1991 Mardoum, R., Bejar, R., and Merritt, T.A. Controlled study of the effects of indomethacin on cerebral blood flow velocities in newborn infants. *J. Pediatrics* 118: 112-115.
 95. 1991 Merritt, T.A., Hallman, M., Berry, C., Pohjavuori, M., Edwards, D.K., Jaaskelainen, J., Garfe, M., Vaucher, Y., Wozniak, P., Heldt, G. and Rapola, J. Randomized, placebo-controlled trial of human surfactant

given at birth versus rescue administration in very low birth weight infants with lung immaturity. J. Pediatrics 118: 581-594.

96. 1991 Revak, S.D., Merritt, T.A., Hallman, M., Heldt, G., La Polla, R.J., Hoey, K., Houghten, R.A., and Cochrane, C.G. The use of synthetic peptides in the formation of biophysically and biologically active pulmonary surfactants. Pediatric Research 29: 460-465.
97. 1991 Strayer, D.S., Hallman, M., and Merritt, T.A. Immunogenicity of surfactant.I. Human Alveolar Surfactant. Clinical Experimental Immunology 83: 35-40.
98. 1991 Strayer, D.S., Hallman, M., and Merritt, T.A. Immunogenicity of surfactant. II. Porcine and bovine surfactant. Clinical Experimental Immunology 83: 41-46.
99. 1991 Hallman, M., Phojuvuori, M., Bry, K., and Merritt, T.A. Neonatal surfactant deficiency and surfactant replacement therapy. International Journal of Technology Assessment in Health Care 7: (Suppl 1): 21-25.
100. 1991 Gilbert, W.M., Davis, S.T., Kaplan, C., Pretorius, D., Merritt, T.A. and Benirschke, K. Morbidity associated with prenatal disruption of the dividing membrane in twin gestation. Obstetrics and Gynecology 78: 623-630.
101. 1991 Levine, D., Edwards, D.K., and Merritt, T.A., Synthetic vs Human surfactants in the treatment of respiratory distress syndrome: Radiographic findings. Am. J. of Roentgenology 157: 371-374.
102. 1991 Hallman, M., Merritt, T.A., Akino, T., and Bry, K. Surfactant protein A, phosphatidylcholine and surfactant inhibitors in epithelial lining fluid. Correlation with surface activity, severity of respiratory distress syndrome and outcome in small premature infants. American Review of Respiratory Diseases 144: 1376-1384.
103. 1991 Eijking, E.P., Strayer, D.S., van Dall, G.J., Tenbrink, R. Merritt, T.A., Hannappel, E., and Lachmann, B. *In vivo* and *In vitro* inactivation of bovine surfactant by an anti-surfactant monoclonal antibody. European Respiratory Journal 4: 1245-1250.
104. 1992 Gilliard, N., Pappert, D., Merritt, T.A., Heldt, G. And Spragg, R. Radiolabelling of the hydrophobic components of lung surfactant with 3-(Trifluoromethyl) -3-(-m-[I₁₂₅] iodophenyl) diazirine. Analytical Biochemistry 193: 310-315.
105. 1992 Moulton, S.L., Krous, H.F., Merritt, T.A., Odell, R., Gangitano, E., and Cornish, J.D. Congenital pulmonary alveolar proteinosis: failure

- of treatment with extracorporeal life support. *J. Pediatrics* 120: 297-302.
106. 1992 Heldt, G.P., Merritt, T.A., Golembeski, D., Gillard, N., Bloor, C. and Spragg, R. Distribution of surfactant, lung compliance, and aeration of preterm rabbit lungs after surfactant therapy and conventional and high-frequency oscillatory ventilation. *Pediatric Research* 31: 270:275
 107. 1992 Plopper, C.G., St. George, J.A., Read, L.C., Nishio, S.J., Weir, A.J., Edwards, L., GTarantal, A.F., Pinkerton, K.E., Merritt, T.A., Whitsett, J., George-Nascimento, C. and Styne, D.M. Acceleration of alveolar type II cell differentiation in fetal rhesus monkey lung by administration of EGF. *American Journal of Physiology* 262 (Lung Cell Molecular Physiology) (6) L313-L321.
 108. 1992 Merritt, T.A. Factors to consider when selecting a surfactant. *Journal of Perinatology-Neonatology* 5: 30-34.
 109. 1992 Harker, L.C., Merritt, T.A., Edwards, D.K. Improving the prediction of surfactant deficiency in very low birthweight infants with respiratory distress. *Journal of Perinatology* 12: 129-133.
 110. 1992 Merritt, T.A. Surfactant Replacement Therapy. Sooner or later: Does it make a difference? *Journal of Perinatology-Neonatology* 4: 20-23.
 111. 1993 Vaucher, Y.E., Harker, L., Merritt, T.A., Hallman, M., Gist, K., Bejar, R., Heldt, G.P., Edwards, D. And Pohjavuori, M. Outcome at twelve months of adjusted age in very low birth weight infants with lung immaturity: a randomized, placebo-controlled trial of human surfactant. *J. Pediatrics* 122: 126-132.
 112. 1993 Merritt, T.A., Saeed, D. Emergent management of the newborn, pp 615-624 In T.R. Moore, R.C. Reiter, R.W. Rebar and V.V. Baker (Eds) *Gynecology and Obstetrics: A Longitudinal Approach*. Churchill Livingstone, New York, NY.
 113. 1994 Soll, R., Merritt, T.A., Hallman, M. Clinical responsiveness to surfactant. Pp. 49-80. In A. Jobe, B. Boynton, and J. Whitsett (Eds) *Surfactant Therapy*. Cambridge University Press, Cambridge, United Kingdom.
 114. 1992 Merritt, T.A., White, R., and Maynard, A. Early versus delayed neonatal administration of a synthetic surfactant-the judgment of OSIRIS. *Lancet* 340: 1363-1369. (only U.S. participants among international group of authors).
 115. 1992 O'Brodovich, H. and Merritt, T.A. Bicarbonate concentration in rhesus monkey and guinea pig fetal lung fluid. *American Review of*

Respiratory Diseases 146: 1613-1614.

116. 1992 Spragg, R.G., Gillard, N., Richman, P., Smith, R.M., Hite, D., Pappert, D., Heldt, G.P. and Merritt, T.A. The adult respiratory distress syndrome: clinical aspects relevant to surfactant supplementation, pp. 685-703. In B. Robertson, L.M.G. van Golde, and J.J. Battenburg (Eds). Pulmonary Surfactant. Elsevier, New York, N.Y.
117. 1993 Hallman, M., Merritt, T.A., Bry, K. and Berry, C. Association between neonatal care practices and efficacy of exogenous human surfactant: results of a bicenter randomized trial. *Pediatrics* 91: 552-560.
118. 1993 Merritt, T.A., Soll, R.F., and Hallman, M. Overview of exogenous surfactant replacement therapy. *Journal of Intensive Care Medicine* 8: 205-228.
119. 1993 Pramanik, A.K., Holtzman, R.B., and Merritt, T.A. Surfactant replacement therapy for pulmonary diseases. *Pediatric Clinics of North America* 40: 913-936.
120. 1993 Merritt, T.A., Amirkhanian, J.D., Helbock, H., Halliwell, B. and Cross, C.E. Reduction of the surface-tension-lowering ability of surfactant after exposure to hypochlorous acid. *Biochemical Journal* 295: 19-22.
121. 1993 Pesonen, E., Heldt, G.P., Merritt, T.A., Sahn, D.J., Elias, W., Tikkanen, I., Fyhrquist, F. and Andersson, S. Atrial natriuretic factor and pulmonary status in premature infants with respiratory distress syndrome: preliminary investigation. *Pediatric Pulmonology* 15: 362-364.
122. 1994 Simko, A., Mardoum, R., Merritt, T.A., and Bejar, R. Effects on cerebral blood flow velocities of slow and rapid infusion of indomethacin. *Journal of Perinatology* 14: 29-35.
123. 1994 Goetzman, B.W., Read, L.C., Plopper, C.G., Tarantal, A.F., George-Nascimento, C., Merritt, T.A., Whitsett, J.A., and Styne, D. Prenatal exposure to epidermal growth factor attenuates respiratory distress syndrome in rhesus infants. *Pediatric Research* 35: 30-36.
124. 1994 deMello, D.E., Nogee, L.M., Heyman, S., Krous, H.F., Hussain, M., Merritt, T.A., Hsueh, W., Haas, J.E., Heidelberger, K., Schumacher, R., and Colten, H.R. Molecular and phenotypic variability in the congenital alveolar proteinosis syndrome associated with inherited surfactant protein B deficiency. *J. Pediatrics* 125: 43-50.
125. 1994 Wiswell, T.E., Peabody, S.S., Davis, J.M., Slayter, M.V., Bent, R.C., and Merritt, T.A. Surfactant therapy and high-frequency jet

ventilation in the management of a piglet model of meconium aspiration syndrome. *Pediatric Research* 36: 494-500.

126. 1994 Soll, R.F., Merritt, T.A., and Hallman, M. Surfactant in the prevention and treatment of respiratory distress syndrome, pp 49-80. In B.R. Boynton, W.A. Carlo and A.H. Jobe (Eds), *New Therapies for Neonatal Respiratory Failure: A Physiologic Approach*. Cambridge University Press, Cambridge, United Kingdom.
127. 1994 Sherman, M.P., Campbell, L.A., Merritt, T.A., Long, W.A., Gunkel, H., Curstedt, T. and Robertson, B. Effect of different surfactants on pulmonary group B streptococcal infection in premature rabbits. *J Pediatrics* 125: 939-947.
128. 1994 Gilliard, N., Heldt, G.P., Loreda, J., Gasser, H., Redl, H., Merritt, T.A. Spragg, R.G. Exposure of the hydrophobic components of procine lung surfactant to oxidant stress alters surface tension properties. *Journal of Clinical Investigation*. 93: 2608-2615.
129. 1994 Hallman, M., Merritt, T.A., and Bry, K. The fate of exogenous surfactant in neonates with respiratory distress syndrome. *Clinical Pharmacokinetics* 26: 215-232.
130. 1994 Amirkhanian, J.D. and Merritt, T.A. The influence of pH on surface properties of lung surfactants. *Lung* 173: 243-254.
131. 1995 Merritt, T.A., Hallman, M., Vaucher, Y., Turner, T., and Wilson, M.J. Outcomes of surfactant treated infants: analysis of developmental outcomes and the economic impact of surfactant therapy, pp 601-620. In B. Robertson and W. Taeusch (Eds) *Surfactant Therapy for Lung Disease*. Marcel Dekker, Inc., New York, N.Y.
132. 1995 Hallman, M., Sills, J., Bry, K., Merritt, T.A. Biochemical prediction of response to surfactant therapy in the newborn infant, pp 32-348. In B. Robertson, H.W. Taeusch (Eds). *Surfactant Therapy for Lung Disease*. Marcel Dekker, Inc. New York, N.Y.
133. 1995 Merritt, T.A., Kheiter, A., and Cochrane, C.G. Positive end-expiratory pressure during KL4 surfactant instillation enhances intrapulmonary distribution in a simian model of respiratory distress syndrome. *Pediatric Research* 38: 211-217.
134. 1995 Strayer, D.S., Merritt, T.A., and Hallman, M. Levels of SP-A-anti SP-A immune complexes in neonatal respiratory distress syndrome correlated with subsequent development of bronchopulmonary dysplasia. *Acta Paediatrica* 84: 128-131.
135. 1995 Robbins, C.G., Davis, J.M., Merritt, T.A., Amirkhanian, J., Sahgal, N.,

- Morrin III, F.C., and Horowitz, S. Combined effects of nitric oxide and hyperoxia on surfactant function and pulmonary inflammation. American Physiological Society. Am. J. Physiol. 269 (Lung Cell. Mol. Physiol) (13): L545-L550.
136. 1996 Cochrane, C.G., Revak, S.D., Merritt, T.A., Heldt, G.P., Hallman, M., Cunningham, M., Easa, D., Pramanik, A., Edwards, D.K., Alberts, M.S. The efficacy and safety of KL4-surfactant in preterm infants with RDS. Journal of Respiratory and Critical Care Medicine 153 (1): 404-410.
 137. 1996 Revak, S., Merritt, T.A., Cochrane, C.G., Heldt, G.P., Alberts, M., Anderson, D.W., and Kheiter, A. Efficacy of synthetic peptide-containing surfactant in the treatment of respiratory distress syndrome in preterm infant rhesus monkeys. Pediatr. Res. 39: 114-124.
 138. 1996 Manalo, E., Merritt, T.A., Kheiter, A., Amirkhanian, J. and Cochrane, C.G. Comparative effects of some serum components and proteolytic products of fibrinogen on surface-tension lowering abilities of beractant and a synthetic peptide containing surfactant KL4. Pediatr. Res. 39: 540-545.
 139. 1996 Hallman, M., Merritt, T.A. Lack of GM-CSF as a cause of alveolar proteinosis [editorial] J. Clin. Invest. (97) 3: 589-90.
 140. 1996 Korte, C., Styne, D., Merritt, T.A., Mayes, D., Wertz, A., and Helbock, H. Adrenocortical insufficiency in the very low birth weight infant: improved testing sensitivity and association with neonatal outcome. J. Pediatr. 128: (2) 257-63.
 141. 1996 Pappert, D., Gilliard, N., Heldt, G. Merritt, T.A., Wagner, P.D., Spragg, R. Effect of N-nitroso-N-methylurethane on gas exchange, lung compliance, and surfactant function of rabbits. Intensive Care Med. 22: 345-352.
 142. 1996 Merritt, T.A. and Heldt, G. Partial Liquid Ventilation: The Future is Now [editorial] New England Journal of Med. 335: 814-815.
 143. 1996 Merritt, T.A., Palmer, D., Bergman, D.A., Shiono, P. Clinical Practice Guidelines in Pediatric and Newborn Medicine: Implications for their use in practice. Pediatrics 99: 100-114.
 144. 1997 Andersson, S., Merritt, T.A., Orpana, A., Viinikka, L., Ylikorkala, O. High Endothelin-1 in the Airways of Preterm Infants Is Associated with Less Severe Respiratory Distress During the Early Postnatal Period. Pediatrics. 99: 545-547.
 145. 1997 Manalo, E., Merritt, T.A., Amirkhanian, J., Kheiter, A. Inactivation of

Surfactant by Fibrinogen: A comparison of two surfactant preparations. *Lung* 45: 97-104.

146. 1997 Robbins, C.G., Horowitz, S., Merritt, T.A., Kheiter, A., Tierney, J., Narula, P., Davis, J.M. Recombinant human SOD reduces lung injury caused by inhaled nitric oxide and hyperoxia. *Am J. Physiol.* 272(5Pt1): L903-907.
147. 1998 Amirkhanian, J.D., Merritt, T.A. Inhibitory effects of oxyradical on surfactant function utilizing *in vitro* Fenton reaction. *Lung* 176 (1) 63-72.
148. 1998 Raddish, M., Merritt, T.A. Early Discharge of Premature Infants. *Clin. Perinatology* 25: 499-520.
149. 1998 Cochrane, C.G., Revak, S., Merritt, T.A., Schraufstatter, I.U., Hoch, R.C., Henderson, C., Andersson, S., Takamori, H., Oades, Z. Bronchoalveolar Lavage with KL4-Surfactant in Models of Meconium Aspiration Syndrome. *Pediatr. Res.* 44 : 705-715.
150. 1998 Merritt, T.A., Raddish, M. A review of guidelines for the discharge of premature infants: Opportunities for improving cost effectiveness. *J. Perinatology* 18: 527-537.
151. 1999 Merritt, T.A., Gold, M., Holland J.A. Critical Evaluation of Clinical Practice Guidelines in Neonatal Medicine: Does their use Improve Quality and Lower Costs? *J. Evidence Based and Quality Care Medicine* (5) : 169-177.
152. 1999 Andersson, S., Merritt, T.A., Amirkhanian, J. Oxidative Inactivation of Surfactant. *Lung* 177: 1798-1809.
153. 1999 Merritt, T.A., Boehm, P., Gold, M., Holland, J. Home gavage feeding support as an adjunct to breast feeding in premature infants. *AAP District VIII Section on Perinatal Medicine. ePediatrics* May 28-30.
154. 1999 Merritt, T.A. Exogenous Surfactant Administration for Respiratory Distress Syndrome. pp 55-68. In *Neonatal Intensive Care Handbook* (Eds) Goetzman, B. and Wennberg, R., Mosby Publishers, San Fransisco, Ca.
155. 2000 Levine, C.R., Kazzaz, J.A., Koo., J.C., Merritt, T.A., Matalon, S., Pollack, S., Davis, J. The effects of variable concentrations of inhaled nitric oxide and oxygen on the lung of newborn piglets. *Am J. Physiol.* 195: 2035-2039.
156. 2002 Wiswell, T.E., Knight, G.R., Finer, N.N., Donn, S.M., Desai, H., Walsh,

- W.F., Sekar, K.C., Bernstein, G., Keszler, M., Visser, V., Merritt, T.A., Mannino, M., Mastrioianni, L., Marey, B., Revak, S., Cochrane, G.G. A Multicenter, Randomized, Controlled Trial Comparing the Safety and Effectiveness of Surfaxin (Lucinactant) to Standard of Care for Treatment of the Meconium Aspiration Syndrome (MAS) in Newborn Infants. *Pediatrics* 109(6): 1081-1087.
157. 2002 Levine, C.R., Kazzaz, J.A., Koo, K.C., Chester, D., Merritt, T.A., Matalone, S., Pollack, S., Davis, J.M. The Effects of Variable Concentrations of Inhaled Nitric Oxide and Oxygen on the Lung of Newborn Piglets. *Pediatr. Pulmonology*. 34: 58-65.
 158. 2002 Merritt, T.A., Wiswell, T.A., Niven, R. Expanded Uses of Surfactant: New Diseases and New Challenges. *Biology of the Neonate* 82: 281-282.
 159. 2003 Merritt, T.A., Pillers, D.A., Prows, S. Early Discharge of the Premature Infant: A Critical Analysis. *Seminars in Neonatology* 8: 95-115.
 160. 2004 VanArsdale, J.L., Leiker, R., Kohn, M., Merritt, T.A., Horowitz, B. Lead poisoning from a toy necklace. *Pediatrics* 114(4) 1096-1099.
 161. 2004 MMWR Brief Report: Lead Poisoning from Ingestion of a Toy Necklace, Oregon 2003 VanArsdale, J.L., Merritt, T.A., Peddycord, D. June 19, 2004 53(23) 509-511.
 162. 2004 Moya, F., Gadzinowski, J., Bancalari, E., Salinas, V., Kopelman, B., Bancalari, A., Kornacka, K., Merritt, T.A., Segal, R., Schaber, C., Tsai, W., Massaro, J., D'Agostino, R., Packer, M. Randomized Trial of Lucinactant versus Colfosceril Palmitate with a Beractant Control For Prophylaxis of Respiratory Distress Syndrome in Very Preterm Infants. *Pediatrics* 115(4): 1018-1029.
 163. 2006 Mazela, J. Merritt, T.A., Gadzinowski, J., Sinha, S. Evolution of pulmonary surfactants for the treatment of neonatal RDS and Pediatric Lung Disease. *Acta Paediatrica* 95(9): 1036-1048.
 164. 2007 Mazela, J. Merritt, T.A., Finer, N.N. Aerosolization of Surfactant and Continuous Positive Airway Pressure. *Current Opinion in Pediatrics* 29: 50-57.
 165. 2007 Natarajan, G., Aggarwal, S., Merritt, T.A. A Novel Mutation Associated with congenital hyperinsulinism. *Am J. Perinatology*; 24: 401-404.
 166. 2007 Merritt, T.A. Natarajan, G. Trisomy 14 Mosaicism: A case without neurodevelopmental delay and a review of the literature. ; 2: 563-569
 167. 2009 Ibrahim, Y., Merritt, T.A., Barash, J., Arnon, S. Infant Botulism in the NICU, *NeoReviews*, January., 2009

168. 2009 Merritt, T.A., Deming, D., Boynton, B. The New Bronchopulmonary Dysplasia: Comments and Challenges, Seminars in Neonatology (in press)
169. 2009 Nkadi, P.O., Merritt, T.A., Pillars, D.A. Molecular Mechanisms in the Metabolism of Pulmonary Surfactant: A Review. Mole. Genetics and Metabolism. J. Metabolism and Genetics 2009, 15: 279-301

BOOKS

1. 1979 Miller, H.C. and Merritt, T. A. FETAL GROWTH IN HUMANS, Yearbook, Medical Publications, Chicago, Ill
2. 1983 Ziai, M., Clarke, T., Merritt, T.A. ASSESSMENT OF THE NEWBORN Churchill Publications, Philadelphia, Pa.
2. 1988 Merritt, T.A., Boynton, B., Northway, W. BRONCHOPULMONARY DYSPLASIA, Blackwell Scientific Publishers, London, United Kingdom

LETTERS TO THE EDITOR

1. 1991 Merritt, T.A. and Boynton, B. The BPD Problem Pediatrics 88(1): 1899-1900.
2. 1994 Merritt, T.A., Boynton, B.R. and Hallman, M. Viability of Infants Born at 22 to 25 weeks gestation. New England Journal of Medicine 330(17): 1234-1235.
3. 1994 Merritt, T.A. Surfactant therapy in extremely premature infants. J. Pediatrics 125(1): 172-173.
4. 1995 Fanning, S., Ishisaka, D.Y., and Merritt, T.A. Possible metochlopramide induced increase in serum aldosterone in a premature infant Am J. Health Syst. Pharm. 52: 319-320.
5. 2005 Merritt, T.A. Author's Replay: Lead Poisoning from a toy necklace. Pediatrics 116(4) 1050-1051.
6. 2006 Merritt, T.A. Concerning the Article by T. Curstedt and J. Johansson:

New Synthetic Surfactants-Basic Science. *Biology of the Neonate* 89(4): 257-258.

INVITED BOOK CHAPTERS

1. 1974 Kenton, C. and Merritt, T.A. Review of reaction to infant deaths by family members, social and legal institutions. *National Library Medicine*. In *Sudden Death in Infancy*, pp 74-93, Government Printing Office, 74-069.
2. 1974 Kenton, C. and Merritt, T.A. Review of Low Birth Weight Infants: Causation, Complications and Development. *National Library of Medicine*, In *Low Birth Weight*, pp 101-120 Government Printing Office 74-149
3. 1975 Steinschneider, A. and Merritt, T.A. Recognition of infants at risk for sudden infant death syndrome: Summary of Workshop, NICHD, NIH publication.
4. 1977 Merritt, T.A., Werthammer, J., Gluck, L. In *Neonatal Pulmonary Emergencies*. Shibel, E. and Moser, K.L. pp 252-260 (eds) C.V. Mosby, Chicago, Illinois
5. 1978 Merritt, T.A., Obladen, M., Gluck, L. Biochemical maturation of pulmonary phospholipids. Pp 103-124 In U. Stave (ed) *Perinatal Physiology*, Plenum, New York, N.Y.
6. 1978 James, L.S. and Merritt, T.A. Respiratory Distress Syndrome, pp 535-545. In E. Phillip, J. Barnes and M. Newton (Eds) *Scientific Foundations of Obstetrics and Gynecology*. Blackwell Scientific Publishers, London, United Kingdom.
7. 1980 Merritt, T.A., Miller, R.K., and Zmora, E. Expanded use of amniotic fluid phospholipids for determining pulmonary maturation in utero. pp 389-399 In J.C. Touchstone and D. Rogers (Eds). *Thin layer chromatography: Quantitative Environmental and Clinical Applications*, CRC Publications, Boca Raton, Florida
8. 1980 Merritt, T.A., Saunders, B.L., and Gluck, L. Assessment of pulmonary maturation. pp 101-121. In S. Alajem (Ed), *Clinical Perinatology*, C.V Mosby, Chicago, Illinois.
9. 1980 Merritt, T.A. and Gluck, L. Care of the High Risk Neonate: Klaus, M.H. and Fanaroff, A.A. (Eds) In *New England Journal of Medicine* 303: 468 (book review)
10. 1980 Merritt, T.A. *Diagnosis and Management of Fetus and Neonate at Risk*

In Babson, S.G., Pernoll, M., and Benda, G. (Eds) New England Journal of Medicine 303: 468 (book review)

11. 1982 Zmora, E., Merritt, T.A. and Gluck, L. Pulmonary disorders in the neonatal period. pp35-51 in Moser, K (Ed) C.V. Mosby, Chicago, Illinois
12. 1982 Merritt, T.A. Crib death: The sudden infant death syndrome. Guntheroth, W. (Ed) New England Journal of Medicine 307: 450 (book review)
13. 1984 Merritt, T.A. and Valdez-Dapena, M. Infants of adolescent mothers In Adolescent Pregnancy, McCarneny, E.R. (Ed) in Monographs in Neonatology, Grune and Stratton, Philadelphia, Pa
14. 1986 Stein, M. and Merritt, T.A. Foundations in Pediatrics, Ed. E. First and Avery, M.E. (eds) Lippincott, New York, NY. New England Journal of Medicine (Book Review)

LIMITED DISTRIBUTION

1. 1991 Hallman, M., Merritt, T.A., Berry, C. Who doesn't respond to surfactant therapy? Hot Topics in Neonatology. Syllabus Conference sponsored by Ross Laboratories. Washington, D.C. pp 146-164.
2. 1991 Hallman, T.A. and Merritt, T.A. Should tests to done to prove surfactant deficiency? Hot Topics in Neonatology Syllabus, Conference sponsored by Ross Laboratories. Washington, D.C. pp 171-176.
3. 1992 Merritt, T.A. What are the respiratory effects of prenatal exposure to cocaine? Journal of Respiratory Disease 13(8): 1078.
4. 1993 Merritt, T.A. Surfactant administration and its influence on peri-ventricular-intraventricular hemorrhage. Roundtable Symposium on Surfactant Safety Issues. Syllabus. Conference sponsored by Burroughs-Wellcome Co., Washington, D.C. pp 25-29.